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- Severe acute respiratory syndrome-related coronavirus
(SARS-CoV) and Middle East respiratory syndrome-
related coronavirus (MERS-CoV) belong to the
Coronaviridae family (CoVs).
- They are enveloped viruses with a positive-sense single-
stranded RNA genome, which can infect a wide variety of
animals, including humans, causing severe respiratory
diseases (e.g., SARS and MERS).
- Human-to-human transmission is the most common route.
- There are NO specific treatments or vaccines available.
- Both diseases are considered severe emerging
infectious diseases of the 21st century.
- VSV is an enveloped virus enclosing a nonsegmented,
negative-sense single-stranded RNA.
- It belongs to the Rhabdoviridae family and it naturally
infects livestock, but rarely humans.
- Recombinant VSV is one of the most promising
vaccine platforms.
WHY IS IT USED AS A VECTOR?
ü Low risk of pre-existing immunity.
ü Replication in almost all mammalian cell lines.
ü Strong induction of immune response.
ü Used as an attenuated vectorà deletion of the 
viral glycoprotein (G) gene.
ü G protein can be replaced for other virus 
glycoproteins.
- The spike protein (S) of human CoVs recognizes and binds to the
host cell receptor. It is a surface-located glycoprotein formed by a
signal peptide and two subunits: S1 and S2 (Fig. 1).
- The receptor-binding domain (RBD) is located in the S1 subunit
(Fig. 1). RBD is responsible for the interaction with the cell
receptor. SARS-CoV and MERS-CoV RBDs are highly similar.
GENERAL INFORMATION [1,2] VESICULAR STOMATITIS VIRUS (VSV) [3,4] S PROTEIN AND RECEPTOR-BINDING DOMAIN [2]
HYPOTHESIS & OBJECTIVE
A successful immunization against SARS-CoV and MERS-
CoV can be achieved in mice by developing a vaccine based
on recombinant vesicular stomatitis viruses (rVSVs) which
express the RBD of the S protein of each coronavirus.
PASSIVE PROTECTION STUDY [7,8]
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VECTOR CONSTRUCTION AND rVSV RECOVERY [5,6] ANIMAL VACCINATION AND SAMPLE COLLECTION [7,8]
• SARS-CoV and MERS-CoV RBD regions are subcloned into pVSVFL(+) under
the control of T7 polymerase promoter, resulting in the plasmids pVSV-
RBDSARS and pVSV-RBDMERS, respectively.
• pVSVFL(+) is a plasmid DNA construct that expresses the complete VSV
positive-strand (antigenomic) RNA, and it is used as the carrier for the two
exogenous proteins.
• rVSV-RBD/S (SARS-CoV), rVSV-RBD/M (MERS-CoV) and wild-type (WT)
rVSV vectors are recovered in BHK-21 cell cultures.
IMMUNOFLUORESCENCE ASSAY AND TITRATION OF rVSV VECTORS [6,7]
Detection of SARS/MERS-CoV RBD expression is done by indirect
immunofluorescence. rVSV vectors (including wild-type rVSV) are titrated by real-
time quantitative PCR.
• SARS/MERS-CoV-neutralizing antibody titers are determined based on the
serum dilution which viral cytopathic effects are inhibited in 50% of the wells.
• VSV-neutralizing antibody titersà highest dilution of serum without evidence
of VSV infection.
NEUTRALIZING ANTIBODY ASSAY [7,8]
Inoculate sera from immunized mice to non-immunized mice:
• rVSV-RBD/S, rVSV-RBD/M or wild-type rVSV immune sera.
• SARS-CoV, MERS-CoV immune sera (C+), or naïve mice sera (C-).
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• Mice inoculated with rVSV-RBD/S, rVSV-RBD/M and WT rVSVà HIGH VSV-
neutralizing antibody titers.
• rVSV-RBD/S or rVSV-RBD/M immunizationà It will generate a STRONG immune 
response against virus infection.
• Lung and nasal turbinate samplesà LOW/UNDETECTABLE virus titers after 
immunization with vaccines.
• Inoculation of rVSV-RBD/S-, rVSV-RBD/M- or SARS-CoV/MERS-CoV antiseraà
PRESENCE of passive protection after virus challenge.
Figure 1. Representation of the genome organization and functional domains of S protein
(in pink) for SARS-CoV and MERS-CoV. The RBD of the S protein is showed in green for
both viruses and the subunits are indicated with brackets. The numbers refer to the amino









The aim of this study is to generate a vaccine that confers
sustained, protective immunity to animal models against
SARS-CoV and MERS-CoV, with the intention of progressing




Figure 2. Generation of rVSV vaccines. A) Representation of pVSVFL(+) designed by Lawson et al. (1995) [5].
Genes encoding VSV proteins (N, P, M, G and L) are shown as arrows. RE sites are shown in the outer circles. RBZ=
ribozyme. B) Sequences of the three rVSV vectors: WT rVSV, rVSV-RBD/S and rVSV-RBD/M. The CD5 signal peptide will
be ligated to the 5’ end of the RBD fragments. VSV glycoprotein (G) gene will be excised by RE digestion. C) Overview of
rVSV recovery, consisting of a co-transfection of vaccinia-T7 infected cells with pVSV-RBDSARS and/or pVSV-RBDMERS,
along with a set of helper plasmids expressing the VSV N, P, G and L proteins. The length of each gene is not represented
accurately. All illustrations are created in BioRender.com.
ALL EXPERIMENTS ARE DONE
IN AN ANIMAL BSL-3 FACILITY
+ BSL-3 LAB.
Figure 3. Chronogram of mice vaccinations, sample collection and virus challenges. Text
enclosed in red describes the sample collection. Created in Microsoft PowerPoint 2019 and
BioRender.com.
5
